ABBREVIATIONS AND ACRONYMS

medicines patent pool

ABC	abacavir
ALD	abacavir/lamivudine/dolutegravir
AMR	Antimicrobial Resistance
ANDA	Abbreviated New Drug Application
API	Active pharmaceutical ingredient
ARV	Antiretroviral
ASCP	American Society of Clinical Pathology
ATOM	Access to Oncology Medicines
ATV	atazanavir
BCS	Biopharmaceutical classification system
BE	Bioequivalence
CAB-LA	Cabotagravir long-acting
CAP	Community Advisory Panel
CHAI	Clinton Health Access Initiative
CKD	Chronic Kidney Diseases
CLHIV	Children living with HIV
CLL	Chronic Lymphocytic Leukemia
CVD	Cardiovascular Diseases
DAC	Daclatasvir
DNDi	Drugs for Neglected Diseases Initiative
DTG	Dolutegravir
EAG	Expert Advisory Group
EASL	European Association for the Study of the Liver
EECA	Eastern Europe and Central Asia
EGFR	Epidermal Growth Factor Receptor
EMA	European Medicines Agency
EML	Essential Medicines List
EoI	Expression of Interest
ESMO	European Society for Medical Oncology
EU-M4All	The European Medicines Agency (EMA), in cooperation with the World Health Organization (WHO), can provide scientific opinions on high priority human medicines, including vaccines, that are intended for markets outside of the European Union (EU). The procedure is called EU-Medicines for all or 'EU-M4all'.
FDC	Fixed dose combination
FTC	Emtricitabine
G/P	glecaprevir/pibrentasvir
G20	Group of twenty
GAP-f	Global Accelerator for Paediatric Formulations
GLP-1	Glucagon-like peptide-1
HbS	Sickle hemoglobin
HCV	Hepatitis C virus
HDV	Hepatitis Delta Virus
HER2	human epidermal growth factor receptor 2
HICs	High income countries
HIV	Human immunodeficiency virus
HPV	Human papillomavirus
HR	Hormone Receptor
IAS	International Aids Society
IDF	International Diabetes Federation
IP	Intellectual property
ITPC	International Treatment Preparedness Coalition
KRAS	Kirsten rat sarcoma virus
LEN	lenacapavir
LMICs	Low- and middle-income countries
LPV	lopinavir
MAGHP	Marketing Authorisation for Global Health Products
MDR-TB	Multi-drug-resistant tuberculosis
MoH	Ministry of Health
MPP	Medicines Patent Pool
MSF	Médecins Sans Frontières
NARCs	Non-AIDS-related comorbidities
NCD	Non-communicable disease
NGO	Non-governmental organisation
NMPA	China National Medical Products Administration
NSCLC	Non Small Cell Lung Cancer
OEB	Occupational Exposure Bands
OEL	Occupational Exposure Limits
PAN-TB	Project to Accelerate New Treatments for Tuberculosis
PEPFAR	President's Emergency Plan for AIDS Relief
PFSCM	Partnership for Supply Chain Management
PHEIC	Public health emergency of international concern
PK	Pharmacokinetics
PLHCV	People living with HCV
PLHIV	People living with HIV
PPH	Post-partum haemorrhage
PrEP	Pre-Exposure Prophylaxis
PROs	Public research organisations
PSA	Prostate-Specific Antigen
r	ritonavir
RMNCH	Reproductive, maternal, newborn and child health
RR-TB	Rifampicin-resistant tuberculosis
RSV	Respiratory Syncytial Virus
SAP	Scientific Advisory Panel
SCD	Sickle Cell Disease
SDC	Swiss Agency for Development Cooperation
SOC	Standard of care
SOF	sofosbuvir
SRAs	Stringent Regulatory Authorities
SSA	Sub-Saharan Africa
Swissmedic MAGHP	Swissmedic procedure for scientific advice and Marketing Authorisation for Global Health Products
T1DM	Type 1 Diabetes
T2DM	Type 2 Diabetes
TAF	Alafenamide
TB	Tuberculosis
The Global Fund	The Global Fund to Fight AIDS, Tuberculosis and Malaria
TLD	tenofovir/lamivudine/dolutegravir
UCLA	University of California Los Angeles
UHC	Universal Health Coverage
UK	United Kingdom
UNAIDS	Joint United Nations Programme on HIV/AIDS
USD	United States Dollar
USFDA	The United States Food and Drug Administration
USFDA Para III	Paragraph III Certification means a certification that a generic applicant seeks FDA approval of its ANDA as of the date a patent listed in the Orange Book for a relevant NDA expires.
WHO	World Health Organization
WHO PQ	WHO Prequalification of Medicines Programme